Maternal drug use in early pregnancy and infant cardiovascular defect

Reproductive Toxicology

Volumn 17, Issue 3, 2003, Pages 255-261

  Källén, Bengt A J ^a   Otterblad Olausson, Petra ^b  

^a UNIVERSITY OF LUND   (Sweden)

^b NATIONAL BOARD OF HEALTH AND WELFARE   (Sweden)

Author keywords

Antihypertensives; Budesonide; Cardiovascular defect; Clomipramine; Erythromycin; Fertility drugs; Naproxen; Nitrofurantoin

Indexed keywords

AMINOSALICYLIC ACID; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; BUDESONIDE; CEFADROXIL; CEPHALOSPORIN DERIVATIVE; CITALOPRAM; CLOMIFENE; CLOMIPRAMINE; CORTICOSTEROID; DICLOFENAC; ERYTHROMYCIN; FERTILITY PROMOTING AGENT; INSULIN; MACROLIDE; NAPROXEN; NITROFURANTOIN; OMEPRAZOLE; PARACETAMOL; PENICILLIN G; PENICILLIN V; PROTON PUMP INHIBITOR; RANITIDINE; SALBUTAMOL; SALMETEROL; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; TERBUTALINE; TETRACYCLINE; UNINDEXED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHROMOSOME ABERRATION; FIRST TRIMESTER PREGNANCY; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEWBORN; PRENATAL DRUG EXPOSURE; REGISTER; RISK ASSESSMENT; SWEDEN;

EID: 0038485691     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0890-6238(03)00012-1     Document Type: Article

References (15)

1. Bossi L. Fetal effect of anticonvulsants. In: Morselli PL, Pippenger CE, Penry JK, editors. Antiepileptic drug therapy in pediatrics. New York: Raven Press; 1983. p. 37-64.
2. Jacobson SJ, Jones K, Johnson K, Ceolin L, Kaur P, Sahn D, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992;339:530-3.
3. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, et al. Retinoic acid embryopathy. N Engl J Med 1985;313:837-41.
4. Ferencz C, Correa-Villaseñor A, Loffredo CA, Wilson PD. Genetics and environmental risk factors of major cardiovascular malformations: the Baltimore-Washington Infant Study: 1981-1989. Perspect Ped Cardiol 5. New York: Futura Publishing Comp., Inc.; 1997.
5. Cnattingius S, Ericson A, Gunnarskog J, Källén B. A quality study of a medical birth registry. Scand J Soc Med 1990;18:143-8.
6. Källén B, Otterblad Olausson P. Monitoring of maternal drug use and infant congenital malformations. Does loratadine cause hypospadias? Int J Risk Saf Med 2001;14:115-9.
7. Källén B. Search for teratogenic risks with the aid of malformation registries. Teratology 1987;35:47-52.
8. Carlgren L-E, Ericson A, Källén B. Monitoring of congenital cardiovascular defects. Pediatr Cardiol 1987;8:247-56.
9. Pradat P, Francannet C, Harris J, Robert E. The epidemiology of cardiovascular defects. Part I. A study based on data from three large registries of congenital malformations. Pediatr Cardiol, 2003, in press.
10. Källén K. Maternal smoking and congenital heart defects. Eur J Epidemiol 1999;15:731-7.
11. Källén B, Otterblad Olausson P, Nygren KG. Neonatal outcome in pregnancies from ovarian stimulation. Obstet Gynecol 2002;100:414-9.
12. Källén B, Otterblad Olausson P. Use of folic acid and delivery outcome: a prospective registry study. Reprod Toxicol 2002;16:327-32.
13. Åberg A, Westbom L, Källén B. Congenital malformations among infants whose mothers had gestational diabetes of preexisting diabetes. Early Human Dev 2001;61:85-95.
14. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol 1999;13:531-6.
15. Ericson A, Källén BAJ. Nonsteroidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol 2001;15:371-5.